CHAPTER ONE
THE DRUG DEVELOPMENT PIPELINE

» Drugs in Worldwide Clinical Development
» Distribution of Global Drug Pipeline by Research Phase
» Worldwide Active R&D Projects in Development
» Distribution of Active Projects in Clinical Phases Only
» Distribution of Global Pipeline by Molecule Type
» Number of Companies with Active Clinical Projects Worldwide
» Top Six Largest Pharmaceutical Company Pipelines
» Most Active Clinical Pipelines
» New Drug Approvals
» Declining Global Clinical Trial Volume
» Worldwide Clinical Trial Initiations
» Percent of Clinical Trials Initiated Outside the US
» Worldwide Clinical Trials Volume
» Distribution of Active Clinical Trials
» Active Phase I Clinical Trials Worldwide
» Active Phase II Clinical Trials Worldwide
» Active Phase III Clinical Trials Worldwide
» Active Phase IV Clinical Trials Worldwide
» Global Compounds in R&D by Therapeutic Area
» Distribution of Global R&D Projects by Therapeutic Area
» Drugs in Clinical Development by Therapeutic Area
» Therapeutic Area Growth

» Most Active Therapeutic Areas
» Worldwide R&D Pipeline by Therapeutic Area (Anabolics–Biopharmaceuticals)
» Worldwide R&D Pipeline by Therapeutic Area (Bone, Cartilage, Connective Tissue System Drugs–Digestive System Drugs)
» Worldwide R&D Pipeline by Therapeutic Area (Drug Addiction & Abuse Drugs–Immunologics)
» Worldwide R&D Pipeline by Therapeutic Area (Motor System Drugs–Wound & Burn Treatment)
» Projects in Development by Therapeutic Area (Anti-cancers–Formulations)
» Projects in Development by Therapeutic Area (Musculoskeletal–Dermatologicals)
» Projects in Development by Therapeutic Area (Blood & clotting–Miscellaneous)
CHAPTER TWO
DRUG DEVELOPMENT PERFORMANCE

**Cycle Time**
- Drug Development Duration: Cycle Time in Years from IND Approval to NDA Approval
- Clinical Approval Times for Drugs and Biopharmaceuticals
- Average Clinical Development Time: Mean Total Development Time in Months
- Clinical and Approval Times
- Cycle Time Acceleration Targets: Phases II-III

**Success Rates**
- Phase Transition Probabilities for All Drugs
- Success Rate Variation by Molecule Size
- NCE Approval Success Rates by Therapeutic Class
- Success Rates by Therapeutic Area and Phase
- Success Rates in Oncology
- Incidence of Project Cancellations
- Estimated Value of Cancellations: Grant Dollars Lost due to Cancellations in Millions
- Traditional Clinical Development Scope, Purpose, and Duration
- Traditional Development Duration
CHAPTER THREE

DRUG DEVELOPMENT ECONOMICS

» Global R&D Spending
» Annual Growth in R&D Spending
» Annual Growth in R&D Spending (cont’d)
» Benchmark R&D Spend as a Percentage of Sales
» R&D Spending as a Percent of Sales by Sector
» Estimated Worldwide R&D Spending as a Percent of Sales
» Benchmark R&D Spending and Annual Growth
» Total Clinical Spending by Phase
» Global R&D Spending by Phase
» Distribution of Total Global R&D Spending
» Direct and Capitalized Cost of Developing a Single Drug
» Total Global Spending on Clinical Development
» Growth in Global Phase I-III Clinical Trial Grant Spending
» Total Spending on Clinical Trial Grants
» Total Clinical Trial Grant Spending
» Mean Cost Per Patient by Phase
» Annual Growth in Per Patient Cost
» Clinical Trial Grant Sources for Academic Centers
» Industry Spending on Clinical Trial Grants by Phase
» Mean Cost Per Patient by Therapeutic Area Across Phases I-III
» Mean Patient Reimbursement Per Visit
» Mean Patient Reimbursement Per Visit by Therapeutic Area Across Phases II & III
CHAPTER FOUR

CLINICAL RESEARCH PARTNERS

Contract Clinical Outsourcing
» Clinical Services Outsourcing
» The Integral Role of CRO Partners: Worldwide R&D Capacity
» Percentage of Budget Dollars Spent on Outsourcing
» Global Market for Contract Preclinical and Clinical Services
» Top CROs by Worldwide Employee Size
» Incidence of Site Management Responsibilities Outsourced to CROs
» Site Responsibilities Outsourced by Company Size
» Site Ratings of Sponsor and CRO Relationship Attributes
» Site Ratings of Sponsor and CRO Study Conduct Support Attributes
» Sponsor and CRO Payment Tardiness: Site Perceptions of Changes in Payment Timeliness
» Clinical Trial Laboratory Services Market Size

Investigative Site Landscape
» Active Unique Investigators Filing Form 1572s World Wide
» Proportion of Novice Investigators Conducting Clinical Trials
» Global Distribution of 1572 Filings
» Distribution of Industry-Funded Clinical Trials in the US
Global Market Share of Active Clinical Trials by Investigative Site Setting

» Comparing Network Size
» Geographic Focus and Scope
» SMOs of Yesteryear
» Number of Clinical Grants Awarded
» Top Investigative Site Operating Concerns
» Distribution of Annual Study Volume per Investigator
» Rising Scope and Declining Size of Clinical Trials
» Site Reported Cancellations
» Site Reported Recovery of Start-Up Costs Associated with Cancellations
» Global Investigative Site Staffing
» Total FTE Employees per Investigative Site
» Mean Number of Employees by Staff Type (Full and Part Time)
» Mean Number of Employees by Staff Type by Region (Full and Part Time)
» Global Investigative Site Mean Revenue and Profitability
» Investigative Site Expenses and Profit
» Type of Accounting Method Used by Investigative Sites
» Wide Differences in Site Payable and Receivable Cycles
» Percentage of Clinical Research Revenue Owed That is Written off as Bad Debt in 2011
CHAPTER FOUR
CLINICAL RESEARCH PRACTICES

Patients / Study Volunteers
» How Many Studies Have You Participated In?
» Most Frequent Illness Addressed?
» How Did You First Contact the Study Center?
» How Much Time Did it Take Before the Study Staff First Contacted You?
» How Long Was The Study?
» How Many Visits Were Required for the Study?
» How Aware Were You About Clinical Trials as a Treatment Option Prior to Learning About this Study?
» Factors Impacting Study Participation
» Factors Reducing Volunteer Willingness to Participate
» Who Helped You Make the Decision to Participate?
» Study Participation Concerns
» How Knowledgeable was Your Physician About Where You Could Find More Information About Active Clinical Trials?
» Were You Compensated for Your Participation in the Study?
» Did You Receive Any Support that Assisted You in Participating?
» Type of Support Received?
» Whom Did You Initially Meet With On Your First Visit?

» Did You Receive an Informed Consent Form Before Beginning the Study?
» Did You Read the Informed Consent Form?
» Who Reviewed the Informed Consent Form with You?
» How Well Did You Understand the Informed Consent Form?
» “I Understood That I May Receive a Placebo (Sugar Pill) Instead of the Investigational Medicine”
» Understanding Study Expectations: Physician Visits and Medication Treatment
» Understanding Study Expectations: Understanding the Risks
» Understanding Study Expectations: Information Received Matched Actual Experience
» Was Medical Care Helpful During the Trial?
» Dropping Out of the Study
» Reasons for Dropping Out
» How Would You Rate the Overall Quality of Care Received During the Study?
» Would You Participate in a Clinical Trial Again?
» Would You Recommend that a Member of Your Family or Friend Participate in a Clinical Study?
CHAPTER FIVE
CLINICAL RESEARCH PRACTICES

Protocol Design
» Rising Protocol Complexity and Burden
» Complexity and Work Burden by Phase
» Impact on Clinical Trial Performance
» Protocol Complexity Impact on Cycle Time
» How Important is Protocol Design to Your Decision to Participate in a Clinical Trial?

Relationship Management and Effectiveness
» Average 2011 Rating of Relationship Quality for a Typical Sponsor
» Sponsor Rating of Overall Relationship Quality
» Regional Comparison - Average Sponsor Ratings
» Average Sponsor Ratings by Site Type
» Average Sponsor Ratings by Years of Experience
» Company Ratings of Relationship Quality
» Company Ratings of Relationship Quality (cont’d)
» Frequency of Attributes in Top 3: “Good / Excellent” Ratings
» Essential Attributes to Study Success
» The Top Sponsors by Essential Attributes
» Evaluating Sponsor Performance: “Better” and “Much Better” Rating
» Evaluating Sponsor Performance: “Worse” and “Much Worse” Rating
» Comparing Performance Quality to Category Importance
» Comparing Attribute Importance to Sponsor Performance - Gaps
» Quality of Staff Professionalism: Sponsor
» Quality of Workstyle: Sponsor
» Quality of General Project Management: Sponsor
» Quality of Study Initiation Process: Sponsor
» Quality of Ongoing Study Conduct: Sponsor
» Quality of Grant Payment Process: Sponsor
» Average 2011 Relationship Quality Rating for the Typical CRO
» Benchmark Proportion of Sites Rating CRO Relationship Quality
» Regional Comparison of Average CRO Ratings
» Average CRO Ratings by Site Type
» Average CRO Ratings by Years of Experience
» The Top Rated CROs
» Site Ratings by Experience and Setting
» Comparing Performance Quality to Category Importance
» Comparing Attribute Importance to CRO Performance - Gaps
CHAPTER FIVE

CLINICAL RESEARCH PRACTICES

» Quality of Staff Professionalism: CRO
» Quality of Workstyle: CRO
» Quality of General Project Management: CRO
» Quality of Study Initiation Process: CRO
» Quality of Ongoing Study Conduct: CRO
» Quality of Grant Payment Process: CRO

Patient Recruitment
» Distribution of Global Development Spending, Trial Volume, and Patient Enrollment
» Probability of Successful Investigative Site Performance
» A Typical Multi-Site Recruitment Pattern
» Preferred Patient Recruitment Methods
» Aggregate Patient Recruitment Success Rates
» Reasons Patients Seek Online Clinical Trials Information
» Individuals Who Would Most Influence Your Decision to Participate

» Top Site Perceived Factors Contributing to Faster Cycle Times
» Factors Contributing Most to Delays in Enrolling the First Patient
» Factors That Most Often Cause Delays
» Factors That Could Best Prevent Future Delays
» Enrollment Delays
» Enrollment Delays by Region
» Percent of Sites Extending Patient Enrollment Period

Section Cover Slide: Development Technology Solutions
» EDC Solutions
» Estimated EHR Market Growth
» Hospital System Adoption of EHRs
» Practicing Physician Adoption of EHR Systems
» Barriers to Hospital System Adoption of EHRs
» Top Barriers to Practicing Physician Adoption of EHRs
CHAPTER SIX
THE GLOBAL PHARMACEUTICAL MARKET

» Global Pharmaceutical Sales
» Year-by-Year Growth in Global Pharmaceutical Sales
» 2010 Global Pharmaceutical Sales by Region
» Largest Therapeutic Areas by Global Pharmaceutical Sales
» Largest Therapeutic Areas by Global Pharmaceutical Sales (cont’d)
» U.S. Generic Market Share of Prescription Sales
» Growth in Worldwide Prescription and OTC Sales by Therapeutic Area: 2008 - 2016
» Growth in Worldwide Prescription and OTC Sales by Therapeutic Area: 2008 - 2016 (cont’d)
» Global Sales Contribution by Age of Drug
» Annual Growth Rate of U.S. Prescription Pharmaceutical Market
» 2010 U.S. Prescription Sales for the Top 10 Therapeutic Classes
» 2010 U.S. Prescription Sales for the Next Top 10 Therapeutic Classes

» Top 12 U.S. Prescription Products by U.S. Sales, 2010
» Next 13 U.S. Prescription Products by U.S. Sales, 2010
» Worldwide Prescription Drugs Sales: Top 10 Companies
» Worldwide Prescription Drugs Sales: Next 10 Companies
» Worldwide Market Share of Prescription Drugs Sales: Top 10 Companies
» Worldwide Market Share of Prescription Drugs Sales: Next 10 Companies
» Worldwide Medical Device Market: Projected Sales
» U.S. Medical Device Market: Projected Sales
» Select Medical Device Manufacturers
» Generic Pharmaceutical Market
» Top 10 Generic Companies
CHAPTER SEVEN
DRUG DEVELOPMENT REGULATION

IND and NDA Submissions and Approvals
» Number of IND Submissions
» Number of INDs Submitted Each Quarter
» Total NDA Submissions and Approvals
» Original NDA / BLA Submissions
» NDA Submissions by Filing Status
» BLA Submissions by Filing Status
» NME Submissions by Filing Status
» Number of NDAs and NMEs Approved
» Approved NDAs and NMEs Receiving Priority Designations
» NMEs Approved with Postmarketing Requirements and/or REMs
» NME / BLA Approvals
» NDA Approvals
» New Biologic Approvals
» FDA Orphan Drug Approvals
» FDA Orphan Drug Designations

Regulatory Review and Approval Cycle Time
» Cycle Time in Years from IND Approval to NDA Approval
» Mean NME Approval Times
» Median Approval Times for Biotech Drugs and Biologics
» Mean EMA Processing Time for Human Medicinal Products

FDA Inspection Results
» FDA, CDER Inspections of Sponsors and CROs
» Complaints Filed Against Investigators
» Complaints Filed Against Investigative Sites as Percentage of Active INDs
» CDER Inspections of Clinical Investigators
» Investigator Deficiencies: Final Classification of OAI
» Bioresearch Monitoring Inspections Overseen by FDAs CDER
» Site Audit Preparedness
» Warning Letters Issued to Principal Investigators
» FDA Inspection Results
» Investigator Disqualifications